On April 17, 2022, the Chinese Academy of Medical Sciences released the "Important Medical Achievements in China in the 21st Century" and "Important Medical Progress in China in 2021" at the China Medical Development Conference. Angiographic quantitative flow ratio-guided (QFR) coronary intervention (FAVOR III China) developed by Prof. Tu Sheng xianand Prof. Chen Yazhu from Shanghai Jiao Tong University was selected in the "Important Medical Advances in China 2021" in the field of clinical medicine China.

The FAVOR III China study was co-led by Prof. Bo Xu and Prof. Shubin Qiao of Fuwai Hospital, Chinese Academy of Medical Sciences, and was conducted by Fuwai Hospital and the School of Biomedical Engineering, Shanghai Jiao Tong University, among others. The results of the 1-year clinical trial were published in the Lancet (Impact factor 79.3) in November 2021. This is the first randomized sham-controlled trial in the cardiovascular field published in The Lancet based on the original Chinese technology. It confirmed that China's original computational QFR-guided coronary can reduce the postoperative risk by 35%, which marks that Chinese original  cardiovascular diagnosis and high-quality clinical research have been recognized by international peers.  

In 2018, QFR successfully passed the innovative review channel of SFDA and obtained the registration certificate of Class III medical device, becoming the first domestic computational coronary physiology product to obtain the certificate of Class III in China. After iteration, the new generation oF QFR technology (μQFR) released in 2020 adds a new intelligent algorithm, and is the first to use the precise coronary reconstruction technology of Murray model, which can quickly and accurately evaluate the physiological function of lesions within 1 minute with only one angle coronary angiography.

Related Links

Xu B, Tu S, Song L, et al. Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial. The Lancet. 2021, 398(10317): 2149-2159. DOI: https://doi.org/10.1016/S0140-6736(21)02248-0.